A Phase 3 interventional study of fenofibrate and metformin fixed combination (drug) in Dyslipidemia/Glucose Metabolism Disorder, sponsored by Solvay Pharmaceuticals. Completed at 25 sites in France. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2007-09-03.
Sponsored by Solvay Pharmaceuticals · Phase 3, Interventional, and Treatment
The primary objective was to assess the acceptability of a 4-week treatment of 4 new fixed-dose combinations of fenofibrate and metformin, in patients with type 2 diabetes and dyslipidemia.
1,073 studies on the registry are indexed under Dyslipidemias; 158 are open to participants now.
This study's enrollment of 69 is below the median of 99 across 842 interventional studies indexed under Dyslipidemias.
Browse Dyslipidemias studies →Solvay Pharmaceuticals is the lead sponsor of 84 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Quotation by Visual Numeric Rating Scale before and after 4-week treatment
Assessment of safety by reporting of Adverse Events
This study is completed, as verified in Aug 2007. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Solvay Pharmaceuticals